Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Ob/Gyn Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Ob/Gyn Other
    Blood Test Can Reduce Repeat Breast MRI in Women With Irregular Menstrual Cycles - (DGNews)
    Flibanserin Provides Multiple Benefits in Women With Low Sexual Desire: Presented at ESSM - (DGDispatch)
    ACOG Recommends Pap Tests for Cervical Cancer Screening Begin Later, With Lower Frequency - (DGNews)
    Flibanserin Effectively Treats Women With Low Libido: Presented at ESSM - (DGDispatch)
    US Panel Ups Age for Routine Breast Cancer Screening From 40 to 50 - (DGNews)

    News archive

     Recent webcasts/CME - Ob/Gyn Other
    • Expert Perspectives on Challenges, Controversies, and Opportunities in Ovarian Cancer Therapy: The Present and the Future
    • Taking Stock of the Current Research: Which New Therapies Are Showing Promise in Ovarian Cancer?
    • Q&A Lightning Round: Expert Opinions on Unanswered Questions and Controversies in Ovarian Cancer
    • Update on DVT and PE in OB Gyn/Ortho Patients
      Hypoactive Sexual Desire Disorder in Women: Implications for Family Practice

      Webcasts/CME archive

       Recent cases - Ob/Gyn Other
        Effects of Growth Hormone Reduction in a Patient with Polycystic Ovary Syndrome Complicated with Acromegaly
        Endometriosis Presenting as an Acute Groin Swelling: A Case Report
        Giant Ovarian Serous Cystadenoma in a Postmenopausal Woman: A Case Report
        Failure of Ultrasound to Diagnose a Giant Ovarian Cyst: A Case Report
        Female Sexual Dysfunction

        Cases archive
          




        my personal edition > ob/gyn other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Presence of Nuclear Atypia Not an Indication of Progression for Low-Grade Cervical Lesions: Presented at ASCP

          By John Otrompke

          CHICAGO -- November 5, 2009 -- Marked nuclear atypia in low-grade lesions are not an indication that the lesions will progress to become high-risk tumours, although they do serve as predictors that the low-grade lesions will recur, researchers noted at the American Society for Clinical Pathology (ASCP) 2009 Annual Meeting. There was no association between human papillomavirus (HPV) and nuclear atypia, either.

          "Some nuclear features are uglier than others," explained Major Rosemarie Rodriguez, MD, Brooke Army Medical Center, Fort Sam Houston, San Antonio, Texas, at a presentation on October 29. "We were trying to see whether the uglier it gets, does it mean anything? In other words, would low-grade cervical lesions with nuclear atypia eventually develop into high-grade lesions? … It didn't pan out that way."

          The study examined 352 consecutive cervical biopsies, divided into 321 cases without marked nuclear atypia, and 31 with atypia (defined as cases with at least 5 epithelial cells with nuclear enlargement and/or multinucleation of at least 5 nuclei). Average follow-up was 14.3 months for those with atypia and 17.9 months for those without atypia.

          High-grade squamous intraepithelial lesions developed in 10.34% of the cases with atypia and 11.68% of those without atypia. While low-grade lesions recurred in 19 of 29 cases with marked nuclear atypia, they recurred in only 114 of 291 cases without atypia (P = .009).

          No significant differences in HPV load were found between the 2 groups.

          "We did follow up the cases for 24 months," said Dr. Rodriguez, noting that a contrary finding would have been significant, because it may have indicated that more frequent follow-up -- such as Pap smears twice a year, or a surgical procedure -- would have been called for. "Being in the military, you can't say no to your Pap test. Whatever diagnosis you get, you can't escape the follow-up," she added.

          According to the literature, 60% of cases of low-grade lesions regress and 30% persist, while between 11% and 13% progress to high-grade lesions that can develop into cervical cancer.

          [Presentation title: The Significance of Marked Nuclear Atypia in Grade 1 Cervical Intraepithelial Neoplasia. Abstract 26]




        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send